<!-- Snapshot captured from live PubMed (public title/abstract metadata).
     Results evolve as the literature grows; re-run to refresh. -->

# Claim Audit Report

## Claim
> BRAF V600E melanoma is associated with response to targeted inhibitor treatment.

## Audit Verdict
**well-supported** (strength +1.00) — supports: 2×clinical; conflicts: none; 35 indirect

## Evidence Map
- Independent sources: 2 supporting, 0 conflicting
- Sentences: 3 supporting · 0 conflicting · 35 indirect
- Records retrieved: 5
- Coverage by claim entity:
  - BRAF (gene): 3 supporting, 16 indirect [pubmed-29540830, pubmed-29610281, pubmed-38631706, pubmed-38972133]
  - melanoma (disease): 1 supporting, 10 indirect [pubmed-29540830, pubmed-29610281, pubmed-35290123, pubmed-38631706, pubmed-38972133]
  - targeted therapy (drug_class): 1 supporting, 1 indirect [pubmed-29540830, pubmed-38972133]

## Supporting Evidence
- [high | clinical | pubmed-29540830@213-358] FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation.
- [high | clinical | pubmed-29540830@1341-1481] These distinct classes of BRAF mutations predict response to targeted therapies and have important implications for future drug development.
- [high | clinical | pubmed-38972133@1325-1488] This review evaluates current and future therapeutic strategies that target metabolic reprogramming in melanoma cells, particularly in response to BRAF inhibition.

## Conflicting Evidence
- None.

## Indirect / Insufficient Evidence
- [high | clinical | pubmed-29540830@101-212] Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase.
- [high | clinical | pubmed-29540830@612-873] As next generation sequencing becomes increasingly used in clinical practice, oncologists are frequently identifying non-V600 BRAF mutations in their patient's tumors, but are uncertain of viable therapeutic options that could be employed for optimal treatment.
- [high | clinical | pubmed-38631706@139-274] Little information is available on the role of the myeloid cell network, especially dendritic cells (DC) during tumor-targeted therapy.
- [high | clinical | pubmed-38631706@275-645] Here, we investigated therapy-mediated immunological alterations in the tumor microenvironment (TME) and tumor-draining lymph nodes (LN) in the D4M.3A preclinical melanoma mouse model (harboring the V-Raf murine sarcoma viral oncogene homolog B (BRAF)V600E mutation) by using high-dimensional multicolor flow cytometry in combination with multiplex immunohistochemistry.
- [high | clinical | pubmed-38972133@0-69] Melanoma metabolism can be reprogrammed by activating BRAF mutations.
- [high | clinical | pubmed-38972133@70-168] These mutations are present in up to 50% of cutaneous melanomas, with the most common being V600E.
- [high | clinical | pubmed-35290123@0-188] Patients with melanoma receiving drugs targeting BRAFV600E and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression.
- [high | clinical | pubmed-35290123@189-370] Based on preclinical studies, intermittent treatment involving alternating periods of drug withdrawal and rechallenge has been proposed as a method to delay the onset of resistance.
- [high | in_vivo | pubmed-29610281@68-192] Directed therapies targeted to oncogenic mutations (such as BRAF V600E) are part of effective late-stage melanoma treatment.
- [high | in_vivo | pubmed-29610281@193-315] However, tumors with BRAF V600E mutations, in approximately 10% of colorectal cancer, are generally treatment-insensitive.

## Citation Audit
- 3/3 cited quotes are verbatim spans of their source (100% faithful).

## Overclaim Flags
- None.

## Contradiction Flags
- None.

## Retrieval Gaps
- None.

## Reviewer Critique (mock)
_Verdict 'well-supported' with 0 audit flag(s); treat the claim as provisional pending the checks below._
- **weak-citation:** All 3 citations are verbatim, but they are single sentences — check they are not quoted out of context.
- **next-source:** Pull an independent, higher-tier source that names the exact claim entities; start beyond pubmed-29540830.

## What Would Change My Mind?
- A well-powered contradicting result, or evidence of publication bias, since nothing currently opposes the claim.

## Suggested Next Checks
- Review cited records manually before drawing scientific conclusions.
- Add model-based claim extraction with citation-grounded outputs.
- Evaluate evidence support with a curated benchmark.

## Limitations
- Uses toy/sample abstracts by default; optional PubMed mode uses public metadata.
- Deterministic stance labeling is a scaffold for a future model-backed extractor.
- Evidence labels are illustrative research signals, not clinical guidance.
- Research signal only — not medical advice, not a validated clinical assessment.
